Brief: Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 In Patients Undergoing Surgery
08/12/2022 13:19
Dec 8 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO INITIATES PHASE II CLINICAL TRIAL EVALUATING
BX1000
IN PATIENTS UNDERGOING SURGERY
* BAUDAX BIO INC- RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL
WILL
STUDY BX1000 IN ABOUT 80 ADULT PATIENTS
* BAUDAX BIO-TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN
REPORTED
IN FIRST GROUP OF PATIENTS ENROLLED, EFFICACY PARAMETERS HAVE
BEEN RECORDED IN TRIAL
* BAUDAX BIO INC- TO ANNOUNCING COMPLETION OF PRE-PLANNED
FIRST
INTERIM ANALYSIS OF BX1000 PHASE 2 SURGERY TRIAL EARLY IN 2023
* BAUDAX BIO INC- TARGET TO COMPLETE FULL STUDY ENROLLMENT
BY END
OF MARCH, 2023
Source text for Eikon: ID:nGNX8f00C5
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer